false
0001756655
0001756655
2026-11-17
2026-11-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 17, 2026
ARDENT HEALTH, INC.
(Exact Name of Registrant as Specified in its
Charter)
| Delaware |
001-42180 |
61-1764793 |
|
(State or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(I.R.S. Employer
Identification No.) |
| 340 Seven Springs Way, Suite 100, Brentwood, Tennessee |
37027 |
| (Address of Principal Executive Offices) |
(Zip Code) |
(615) 296-3000
(Registrant’s Telephone Number, including
Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Common Stock, $0.01 par value per share |
|
ARDT |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
On November 17, 2026,
Ardent Health, Inc. (the “Company”), EGI-AM Investments, L.L.C. (“EGI-AM”), an affiliated entity of Equity Group
Investments, and ALH Holdings, LLC (a subsidiary of Ventas, Inc.) (together with EGI-AM, the “Selling Stockholders”) entered
into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Barclays Capital Inc., as
representatives of the several underwriters named in Schedule 1 thereto (collectively, the “Underwriters”), for the sale by
the Selling Stockholders of 8,000,000 shares of common stock, par value $0.01 per share, of the Company (the “Common Stock”),
at a price to the public of $14.50 per share (the “Offering”). The Offering closed on November 19, 2026. The Company did not
receive any proceeds from the sale of shares of Common Stock by the Selling Stockholders in the Offering.
In connection with the
Offering, the Selling Stockholders have granted the Underwriters a 30-day option to purchase up to an additional 1,200,000 shares of Common
Stock at the public offering price, less the underwriting discounts and commissions.
Also pursuant to the
Underwriting Agreement, on November 19, 2026, the Company repurchased from the Underwriters 1,500,000 shares of Common Stock sold by the
Selling Stockholders in the Offering, at a purchase price equal to $13.7025 per share, which is the price at which the Underwriters purchased
the shares of Common Stock from the Selling Stockholders (the “Concurrent Share Repurchase”). The Company used existing cash
on hand to fund the Concurrent Share Repurchase. The Underwriters did not receive any compensation for the shares repurchased by the Company.
The Concurrent Share Repurchase was not made pursuant to the Company’s previously disclosed stock repurchase program and does not
reduce the approximately $48.0 million of remaining repurchase authorization thereunder.
The Offering was made
pursuant to a shelf registration statement on Form S-3 (File No. 333-289763) filed with the Securities and Exchange Commission (the
“SEC”) on August 21, 2025, and which was declared effective on August 25, 2025 (the “Registration Statement”),
a prospectus, dated August 25, 2025 included as part of the Registration Statement, a preliminary prospectus supplement, dated November
17, 2026 and filed with the SEC on November 17, 2026, and a final prospectus supplement, dated November 17, 2026 and filed with the SEC
on November 18, 2026. The Underwriting Agreement contains certain customary representations, warranties and agreements by the Company
and the Selling Stockholders, conditions to closing, indemnification rights and obligations of the parties and termination rights. The
foregoing description of the terms in the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement,
which is attached hereto as Exhibit 1.1 and incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits:
| Exhibit No. |
Description |
| |
|
| 1.1 |
Underwriting Agreement, dated as of November 17, 2026, by and among Ardent Health, Inc., certain stockholders named therein and J.P. Morgan Securities LLC and Barclays Capital Inc., as representatives of the several underwriters named in Schedule 1 thereto. |
| |
|
| 104 |
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: November
19, 2026 |
ARDENT
HEALTH, INC. |
| |
|
|
| |
By: |
/s/
Stephen C. Petrovich |
| |
Name: |
Stephen C.
Petrovich |
| |
Title: |
Executive
Vice President & General Counsel |